{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:26:16Z","timestamp":1785932776054,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["24-BR-02-03"],"award-info":[{"award-number":["24-BR-02-03"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["24-BR-02-12"],"award-info":[{"award-number":["24-BR-02-12"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["23-BR-05-02"],"award-info":[{"award-number":["23-BR-05-02"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["24-BR-03-01"],"award-info":[{"award-number":["24-BR-03-01"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018749","name":"KBRI","doi-asserted-by":"crossref","award":["24-BR-03-07"],"award-info":[{"award-number":["24-BR-03-07"]}],"id":[{"id":"10.13039\/100018749","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NST","award":["CCL22061-100"],"award-info":[{"award-number":["CCL22061-100"]}]},{"DOI":"10.13039\/501100003665","name":"NIPA","doi-asserted-by":"crossref","award":["H0301-24-1001"],"award-info":[{"award-number":["H0301-24-1001"]}],"id":[{"id":"10.13039\/501100003665","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We previously demonstrated that felodipine, an L-type calcium channel blocker, inhibits LPS-mediated neuroinflammatory responses in BV2 microglial cells and wild-type mice. However, the effects of felodipine on tau pathology, a hallmark of Alzheimer's disease (AD), have not been explored yet. Therefore, in the present study, we determined whether felodipine affects neuroinflammation and tau hyperphosphorylation in 3-month-old P301S transgenic mice (PS19), an early phase AD mice model for tauopathy. Felodipine administration decreased tauopathy-mediated microglial activation and NLRP3 expression in PS19 mice but had no effect on tauopathy-associated astrogliosis. In addition, felodipine treatment significantly reduced tau hyperphosphorylation at S202\/Thr205 and Thr212\/Ser214 residues via inhibiting JNK\/P38 signaling in PS19 mice. Collectively, our results suggest that felodipine significantly ameliorates tau hyper-phosphorylation and tauopathy-associated neuroinflammatory responses in AD mice model for tauopathy and could be a novel therapeutic agent for AD.<\/jats:p>","DOI":"10.1186\/s13041-024-01137-y","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T08:02:50Z","timestamp":1725264170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Felodipine attenuates neuroinflammatory responses and tau hyperphosphorylation through JNK\/P38 signaling in tau-overexpressing AD mice"],"prefix":"10.1186","volume":"17","author":[{"given":"Jeong-Woo","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhan","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yeong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aran","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-8594","authenticated-orcid":false,"given":"Hyang-Sook","family":"Hoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"issue":"10284","key":"1137_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, et al. Alzheimer\u2019s disease. Lancet. 2021;397(10284):1577\u201390.","journal-title":"Lancet"},{"issue":"1","key":"1137_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/19336950.2015.1048936","volume":"10","author":"NJ Ortner","year":"2016","unstructured":"Ortner NJ, Striessnig J. L-type calcium channels as drug targets in CNS disorders. Channels (Austin). 2016;10(1):7\u201313.","journal-title":"Channels (Austin)"},{"issue":"1","key":"1137_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1038\/s41467-019-09494-2","volume":"10","author":"FH Siddiqi","year":"2019","unstructured":"Siddiqi FH, et al. Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing. Nat Commun. 2019;10(1):1817.","journal-title":"Nat Commun"},{"key":"1137_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.csbj.2022.11.049","volume":"21","author":"CA Crossley","year":"2023","unstructured":"Crossley CA, Rajani V, Yuan Q. Modulation of L-type calcium channels in Alzheimer\u2019s disease: a potential therapeutic target. Comput Struct Biotechnol J. 2023;21:11\u201320.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"1137_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1006\/nbdi.1998.0176","volume":"5","author":"R Etcheberrigaray","year":"1998","unstructured":"Etcheberrigaray R, et al. Calcium responses in fibroblasts from asymptomatic members of Alzheimer\u2019s disease families. Neurobiol Dis. 1998;5(1):37\u201345.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"1137_CR6","first-page":"261","volume":"12","author":"T Walton","year":"1993","unstructured":"Walton T, Symes LR. Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. Clin Pharm. 1993;12(4):261\u201375.","journal-title":"Clin Pharm"},{"issue":"21","key":"1137_CR7","doi-asserted-by":"publisher","first-page":"13606","DOI":"10.3390\/ijms232113606","volume":"23","author":"J Kim","year":"2022","unstructured":"Kim J, et al. L-Type Ca(2+) channel inhibition rescues the LPS induced neuroinflammatory response and impairments in spatial memory and dendritic spine formation. Int J Mol Sci. 2022;23(21):13606.","journal-title":"Int J Mol Sci."},{"issue":"8","key":"1137_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477\u201389.","journal-title":"Nat Rev Immunol"},{"key":"1137_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.845185","author":"T Liang","year":"2022","unstructured":"Liang T, et al. The role of NLRP3 inflammasome in alzheimer\u2019s disease and potential therapeutic targets. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.845185.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1137_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41232-018-0085-6","volume":"38","author":"A Nakanishi","year":"2018","unstructured":"Nakanishi A, et al. Amyloid \u03b2 directly interacts with NLRP3 to initiate inflammasome activation: identification of an intrinsic NLRP3 ligand in a cell-free system. Inflam Regener. 2018;38(1):27.","journal-title":"Inflam Regener"},{"issue":"6","key":"1137_CR11","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/glia.24160","volume":"70","author":"IC Stancu","year":"2022","unstructured":"Stancu IC, et al. The NLRP3 inflammasome modulates tau pathology and neurodegeneration in a tauopathy model. Glia. 2022;70(6):1117\u201332.","journal-title":"Glia"},{"key":"1137_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1150940","author":"J-H Park","year":"2023","unstructured":"Park J-H, et al. Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3\u03b1\/\u03b2. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1150940.","journal-title":"Front Immunol"},{"issue":"5","key":"1137_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1755-5949.2010.00177.x","volume":"17","author":"R Medeiros","year":"2011","unstructured":"Medeiros R, Baglietto-Vargas D, LaFerla FM. The role of tau in Alzheimer\u2019s disease and related disorders. CNS Neurosci Ther. 2011;17(5):514\u201324.","journal-title":"CNS Neurosci Ther"},{"key":"1137_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jchemneu.2018.05.006","volume":"92","author":"D Metin-Arma\u011fan","year":"2018","unstructured":"Metin-Arma\u011fan D, et al. Okadaic acid-induced tau hyperphosphorylation and the downregulation of Pin1 expression in primary cortical neurons. J Chem Neuroanat. 2018;92:41\u20137.","journal-title":"J Chem Neuroanat"},{"key":"1137_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.brainres.2010.04.074","volume":"1345","author":"Z Zhang","year":"2010","unstructured":"Zhang Z, Simpkins JW. Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner. Brain Res. 2010;1345:176\u201381.","journal-title":"Brain Res"},{"issue":"5","key":"1137_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","volume":"133","author":"T Guo","year":"2017","unstructured":"Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017;133(5):665\u2013704.","journal-title":"Acta Neuropathol"},{"key":"1137_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bbr.2012.09.040","volume":"237","author":"M Cao","year":"2013","unstructured":"Cao M, et al. Effect of c-Jun N-terminal kinase (JNK)\/p38 mitogen-activated protein kinase (p38 MAPK) in morphine-induced tau protein hyperphosphorylation. Behav Brain Res. 2013;237:249\u201355.","journal-title":"Behav Brain Res"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-024-01137-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13041-024-01137-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-024-01137-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T08:04:11Z","timestamp":1725264251000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/s13041-024-01137-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1186\/s13041-024-01137-y","relation":{},"ISSN":["1756-6606"],"issn-type":[{"value":"1756-6606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"11 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were approved by the institutional biosafety committee (IBC) and performed in accordance with approved animal protocols of the Korea Brain Research Institute (KBRI, Approval No. IACUC-22-00046).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}